Rappaport EB, Salzman A: Once- and twice-daily dos-ing with rosiglitazone improves glycemic control inpatients with type 2 diabetes. Diabetes Care2001;24:308–315. 37. St. John, Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A com-parison of the effects of rosiglitazone and glyburideon cardiovascular function and glycemic control inpatients with type 2 diabetes. Diabetes Care2002;25:2058–2064. 38. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Land- schulz WH: Inhaled insulin provides improved gly-cemic control in patients with type 2 diabetes melli-tus inadequately controlled with oral agents: Arandomized controlled trial. Arch Intern Med2003;163:2277–2282. 39. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y,Nawata H: Effects of a new oral hypoglycaemic agent(CS-045) on metabolic abnormalities and insulin re-sistance in type 2 diabetes. Diabet Med 1994;11:685–691.